William F. Hahne - Concepedia

Author

William F. Hahne

Also Known As

W F Hahne, W Hahne, W. F. HAHNE, W. F. Hahne, W. HAHNE, W. Hahne, WILLIAM F. HAHNE, William F Hahne, William F. Hahne, William Hahne

Publications

1.8K

Citations

H-Index

Concepts

All Affiliations

University of Kansas Medical Center Hôpitaux Universitaires de Strasbourg Roche (France)Sepragen Corporation (United States)OLVG

About

William F. Hahne is an author at University of Kansas Medical Center specializing in medicine, pharmacotherapy, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	15	815
2	Anesthesia	5	5	162
3	Health Sciences	2	2	92
4	Engineering	1	1	33
5	Natural Sciences	1	1	50

William F. Hahne

Publications

1.7K

Citations

H-Index

Page 1

	Year	Citations
Proglumide and benzotript: members of a different class of cholecystokinin receptor antagonists. William F. Hahne, Robert T. Jensen, George F. Lemp, Proceedings of the National Academy of Sciences Gastrointestinal PharmacologyPharmacotherapyExperimental PharmacologyAdenosine 3Gastrointestinal Peptide Hormone	1981	237
Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis Prevention Group. Paul J. Hesketh, Rudolph M. Navari, Thomas Grote, Journal of Clinical Oncology	1996	148
Single-Blind Study of the Effects of Intravenous Dolasetron Mesylate Versus Ondansetron on Electrocardiographic Parameters in Normal Volunteers Claude R. Benedict, Robert Arbogast, Lorene A. Martin, Journal of Cardiovascular Pharmacology	1996	104
Treatment parameters modulating regression of human melanoma xenografts by an antibody–drug conjugate (CR011-vcMMAE) targeting GPNMB Vincent A. Pollack, Enrique Álvarez, Kam Fai Tse, Cancer Chemotherapy and Pharmacology Antibody–drug ConjugateTumor BiologyDrug TargetingMedicineMelanoma	2007	82
Dose-ranging evaluation of the serotonin antagonist dolasetron mesylate in patients receiving high-dose cisplatin. Mark G. Kris, Steven M. Grunberg, R J Gralla, Journal of Clinical Oncology OncologyMedicineDolasetron MesylateMetronomic TherapyClinical Trials	1994	78
Intravenous Dolasetron for the Prevention of Postoperative Nausea and Vomiting After Outpatient Laparoscopic Gynecologic Surgery Sarena G. Graczyk, Ray McKenzie, S. K. Kallar, Anesthesia & Analgesia	1997	74
Intravenous dolasetron and ondansetron in prevention of postoperative nausea and vomiting: a multicenter, double‐blind, placebo‐controlled study K. Korttila, F. Clergue, Jos Leeser, Acta Anaesthesiologica Scandinavica	1997	71
Intravenous Dolasetron for the Prevention of Postoperative Nausea and Vomiting After Outpatient Laparoscopic Gynecologic Surgery Sarena G. Graczyk, Ray McKenzie, S. K. Kallar, Anesthesia & Analgesia GastroenterologyGynecologySurgeryPharmacotherapyPost-operative Care	1997	59
Human dolasetron pharmacokinetics: I. Disposition following single‐dose intravenous administration to normal male subjects Harold Boxenbaum, Todd A. Gillespie, Kathleen Heck, Biopharmaceutics & Drug Disposition Therapeutic Drug MonitoringIntravenous AdministrationPharmacological Study5-Hydroxytryptamine AntagonistMedicine	1992	53
Cholecystokinin (pancreozymin). 3. Synthesis and properties of an analog of the C-terminal heptapeptide with serine sulfate replacing tyrosine sulfate Miklos Bodanszky, Sesha Natarajan, William F. Hahne, Journal of Medicinal Chemistry Tyrosine O-sulfateMedicinal ChemistryC-terminal HeptapeptidePharmaceutical ScienceBiochemistry	1977	50

Page 1